Asunaprevir is an NS3 protease inhibitor used to treat hepatitis C genotype 1b. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
- Mechanism
- Curator reviewed · 2 references
Asunaprevir is a highly active HCV NS3 protease inhibitor. The genome of HCV has a positive polarity which allows it to be translated into a protein in the host cell without further transformation steps. However, the resultant protein needs to be divided by the enzyme NS3 protease into single proteins in order to be able to exert its enzymatic activity or structural role. Therefore, due to NS3 vital importance for viral replication, the inhibiting action of asunaprevir causes a robust antiviral activity.
- Primary indication
- Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.Curator reviewed · 2 structured indications
- Formula / weight
- C35H46ClN5O9S · 748.286 g/mol (avg)
- First approval
- Canada, 2016
- Code names
- BMS-650032
Resolves to
XRWSZZJLZRKHHD-WVWIJVSJSA-NSMILESCOC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2What you can answer from here — as of October 01, 2026
Which drugs share a target with Asunaprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account